2026-06-14T03:30:26Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/89922025-06-24T16:07:10Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_19609col_20.500.12105_16968

00925njm 22002777a 4500 dc Rondy, Marc author Kissling, Esther author Emborg, Hanne-Dorthe author Gherasim, Alin Manuel author Pebody, Richard author Trebbien, Ramona author Pozo Sanchez, Francisco author Larrauri, Amparo author McMenamin, Jim author Valenciano, Marta author I-MOVE/I-MOVE+ group author Delgado-Sanz, Concepcion author Oliva Dominguez, Jesus Angel author Casas Flecha, Inmaculada author 2018 Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates. Euro Surveill. 2018 Mar;23(9):18-00086. 10.2807/1560-7917.ES.2018.23.9.18-00086 1560-7917 1560-7917 Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 29510782 http://hdl.handle.net/20.500.12105/8992 Europe Case control study Influenza Influenza vaccination Influenza vaccine effectiveness Multicentre study Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies